A Phase 3 Randomized, Open-label Study of JNJ-78278343, a T Cell-redirecting agent targeting Human Kallikrein 2, with Docetaxel Versus Docetaxel for Metastatic Castration-Resistant Prostate Cancer (KLK2-PASenger)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
Carlos Alemany -
Sponsor
Janssen Research & Development LLC
Enrollment Form
This study is currently enrolling.
